FDA Grants Entrectinib Breakthrough Designation for NTRK+ Solid Tumors

May 16, 2017 – The FDA has granted a breakthrough therapy designation to entrectinib for use as a treatment for adult and pediatric patients with NTRK-positive, locally advanced or metastatic solid tumors who have either progressed following prior therapies or who have no acceptable standard therapies, according to Ignyta, the manufacturer of the multikinase inhibitor. Breakthrough therapy designation is meant to expedite the development of promising … (leggi tutto)